Claire Davies discusses the FDA's new Operation TrialBlazer initiative, highlighting its potential to accelerate early-stage clinical trials by streamlining investigational new drug (IND) submissions and reducing administrative burdens. She notes that one key proposal, requiring a single institutional review board for multi-site clinical studies, could eliminate duplicative reviews and improve the efficiency of trial activation. The article also points out that while these reforms represent meaningful progress, broader operational challenges beyond the FDA's control will still need to be addressed to significantly speed clinical research in the United States.